Vir Biotechnology, Inc. (VIR)

7,86 +0,04 (+0,51%) A partir del 09:45AM EDT. Mercado abierto.

Vir Biotechnology, Inc.

1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 587

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.	CEO & Director	4,47M	N/A	1969
Dr. Ann M. Hanly Ph.D.	Executive VP & Chief Technology Officer	896,07k	N/A	1970
Dr. Jeff Calcagno M.D.	Executive VP & Chief Business Officer	860,49k	N/A	1961
Dr. Klaus Frueh Ph.D.	Co-Founder & Scientific Advisor	177,66k	N/A	1960
Dr. Lawrence Corey M.D.	Co-Founder & Scientific Advisor	N/A	N/A	1947
Dr. Louis J. Picker M.D.	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Dr. Jennifer Eileen Towne Ph.D.	Executive VP & Chief Scientific Officer	N/A	N/A	N/A
Ms. Heather Rowe Armstrong	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Vanina De Verneuil J.D.	Executive VP, General Counsel & Corporate Secretary	N/A	N/A	N/A
Ms. Arran Attridge	Senior Vice President of Corporate Communications	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de Vir Biotechnology, Inc., a día 1 de septiembre de 2024, es 10. Las puntuaciones base son Auditoría: 4; Tablero: 6; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.